| Previous Close | 70.4800 |
| Open | 71.2400 |
| Bid | 70.2500 x 1100 |
| Ask | 70.2600 x 300 |
| Day's Range | 69.8400 - 71.3700 |
| 52 Week Range | 63.7600 - 88.8500 |
| Volume | 12,926,220 |
| Avg. Volume | 8,066,854 |
| Market Cap | 92.14B |
| Beta | 0.97 |
| PE Ratio (TTM) | 7.45 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.95%) |
| Ex-Dividend Date | 2017-06-14 |
| 1y Target Est | N/A |
- Barrons.com•3 hours ago
Gilead: The Worst is Over?
The sleeping giant has awakened. Which makes it a perfect time for an analyst to start Gilead Sciences' (GILD) stock with a buy rating. It centers on Gilead's valuation, a thesis that "is not new, but is also not necessarily wrong." They explain: While we fully expect Gilead to ultimately (and yes, eventually) pursue and execute on a business development strategy that should prove transformative (and hence render our outlook on the existing business less relevant) we believe concerns around the stock being a "value trap" for investors will soon come to pass.
- TheStreet.com•4 hours ago
Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout
The stock has been on fire.
- Benzinga•6 hours ago
Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...
